Open AccessCan We Personalize Treatment for Kidney Diseases?
Author(s) -
Brad H. Rovin,
Alison M. McKinley,
Daniel J. Birmingham
Publication year - 2009
Publication title -
clinical journal of the american society of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.755
H-Index - 151
eISSN - 1555-905X
pISSN - 1555-9041
DOI - 10.2215/cjn.04140609
Subject(s) - personalized medicine , medicine , precision medicine , kidney disorder , pharmacogenetics , intensive care medicine , pharmacogenomics , nephrology , biomarker , bioinformatics , kidney , pharmacology , pathology , biochemistry , chemistry , gene , genotype , biology
The idea of individualizing therapies to obtain optimal clinical results is not new but has only recently been applied to kidney diseases. Nonetheless, kidney disorders present a variety of opportunities to personalize medicine. Here, the heterogeneity of kidney disorders is reviewed to provide a rationale for pursuing personalized medicine. Data on adjusting therapy on the basis of pharmacogenetics/genomics and pharmacodynamics are summarized to demonstrate where the field is, and biomarker studies that reflect the future of personalized medicine are discussed. The goal of this review is to demonstrate that we can personalize therapy for kidney diseases but that considerable investment in new research will be required for personalized medicine to be routinely used in nephrology clinics.